stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Debt to equity
Genmab A/S Sponsored ADR's debt to equity at the end of the quarter to 30 June 2026 was 0.9×, down 0.0× from fiscal 2025 (0.9×). Over the past ten years it has ranged from 0.0× (fiscal 2024) to 0.9× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | 20.22% |
| FY2021 | 0.0× | 1.67% |
| FY2020 | 0.0× | 39.53% |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.9× | (5.96%) |
| Mar 2026 | 0.9× | 1.62% |
| Dec 2025 | 0.9× | — |
| Sep 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 0.0× |
| RVMD Revolution Medicines, Inc. compare | 0.0× |
| INCY Incyte Corporation compare | 0.0× |
| BNTX BioNTech SE Sponsored ADR compare | 0.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.3× |
| INSM Insmed, Inc. compare | 0.8× |
| GMAB Genmab A/S Sponsored ADR | 0.9× |
| RPRX Royalty Pharma PLC compare | 0.9× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement